Prime Capital Investment Advisors LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 319.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 37,938 shares of the company’s stock after acquiring an additional 28,897 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Zoetis were worth $6,577,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. Plato Investment Management Ltd increased its position in shares of Zoetis by 8.3% during the second quarter. Plato Investment Management Ltd now owns 7,145 shares of the company’s stock worth $1,239,000 after purchasing an additional 546 shares in the last quarter. Diversify Wealth Management LLC acquired a new stake in shares of Zoetis in the second quarter valued at about $2,467,000. Lyell Wealth Management LP lifted its stake in shares of Zoetis by 10.8% in the second quarter. Lyell Wealth Management LP now owns 66,140 shares of the company’s stock worth $11,466,000 after buying an additional 6,460 shares in the last quarter. Prosperity Consulting Group LLC boosted its position in Zoetis by 33.8% during the second quarter. Prosperity Consulting Group LLC now owns 2,774 shares of the company’s stock worth $481,000 after acquiring an additional 701 shares during the last quarter. Finally, OV Management LLC acquired a new position in Zoetis during the second quarter worth about $1,425,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.
Zoetis Price Performance
NYSE:ZTS opened at $191.09 on Monday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The stock’s fifty day moving average is $182.85 and its two-hundred day moving average is $174.14. The company has a market capitalization of $86.57 billion, a P/E ratio of 36.82, a P/E/G ratio of 2.92 and a beta of 0.88. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.
Analyst Upgrades and Downgrades
A number of analysts have commented on ZTS shares. Piper Sandler increased their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Stifel Nicolaus reissued a “buy” rating and set a $200.00 price objective on shares of Zoetis in a research note on Tuesday, August 27th. Finally, Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and an average target price of $217.11.
View Our Latest Report on Zoetis
About Zoetis
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
- Five stocks we like better than Zoetis
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- What is a Special Dividend?
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Investing in Travel Stocks Benefits
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.